Current Report Filing (8-k)
January 15 2019 - 4:58PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 15, 2019
Trovagene, Inc.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-35558
|
|
27-2004382
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
IRS Employer
Identification No.)
|
11055 Flintkote Avenue
San Diego, CA 92121
(Address of principal executive offices)
Registrants telephone number, including area code: (858)
952-7570
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☒
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule
14d-2(b)
under the
Exchange Act (17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule
13e-4(c)
under the
Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter). Emerging growth company ☐
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
The Special Meeting of Stockholders for Trovagene, Inc. (the Company) scheduled for January 15, 2019 has been
adjourned. At the meeting, it was deemed that the holders of a sufficient number of the Companys outstanding common stock have not yet submitted proxies to indicate how their shares should be voted and additional time was needed to collect the
required votes. The Special Meeting will resume at 9:00 a.m. PST on February 12, 2019 at the Companys offices located at 11055 Flintkote Avenue, San Diego, California 92121. The Company will continue to solicit proxies from stockholders
during the period of adjournment. Only stockholders of record on the record date of December 14, 2018 are entitled and are being requested to vote. A copy of the press release announcing the adjournment of the Special Meeting is furnished as
Exhibit 99.1 to
this Form 8-K.
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated: January 15, 2019
|
|
|
TROVAGENE, INC.
|
|
|
By:
|
|
/s/ Thomas Adams
|
|
|
Thomas Adams
|
|
|
Chief Executive Officer
|
3
Cardiff Oncology (NASDAQ:CRDF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cardiff Oncology (NASDAQ:CRDF)
Historical Stock Chart
From Sep 2023 to Sep 2024